Tempus AI, Inc. (TEM) stock analysis: Hold

Bro's Verdict
Deep Dive

Rating

HOLD

Confidence

65%

Target Price

$72.60

Upside

+0.9%

Horizon

medium

Tempus is a scaled AI-in-healthcare asset with a genuine data moat, 23%+ growth, 64% gross margins and a credible path to profitability, but at $71.98 it trades at 8.1x NTM sales — essentially in line with the $72.60 consensus target and the $62-$78 fair value range, leaving little room for execution misses. Aggressive insider selling, elevated leverage and Personalis integration risk tilt the risk/reward to neutral at current levels. The analysis recommends accumulating only on pullbacks toward $55-$60, so the call is HOLD with a target near consensus.

Executive Summary

•Revenue $1.43b TTM growing +23% NTM with raised FY26 guidance of $1.60b, underpinned by 64% gross margins and a scaled multimodal clinical data moat

•Losses narrowing rapidly: NTM EPS of -$0.22 improving to breakeven ($0.03) by FY+2, with Q4 already delivering positive net income of $0.01b

•$1.5b Personalis acquisition positions Tempus to lead the high growth MRD testing market, but adds integration and balance sheet risk given 325% debt/equity

•At 8.1x NTM P/S with the stock at $71.98 versus consensus target of $72.60, upside is largely priced in; heavy insider selling (-$59.7m net, 68 sells vs 0 buys) is a meaningful caution flag

Business Model & Competitive Position

Tempus operates a closed loop precision medicine platform combining clinical diagnostics (NGS based oncology and hereditary testing), a data and analytics business licensing multimodal clinical data to biopharma, and AI enabled clinical applications (Hub, Lens). The flywheel is compelling: every diagnostic test enriches the data library, which increases the value of biopharma licensing deals (AstraZeneca foundation model delivery, Lens platform adoption) and improves test utility. Roughly two thirds of revenue is diagnostics (volume and reimbursement driven) and one third is data/AI (higher margin, recurring). Competitors include Guardant Health, Natera, Foundation Medicine (Roche) and Caris; Tempus differentiates on data depth and AI integration rather than pure test volume.

Financial Snapshot

•Revenue: $1.43b TTM (+23.2% forward growth)

•Gross Margin: 64.0% and expanding

•Operating Margin: -20.1%, improving from prior year

•Net Margin: -17.8% TTM, but Q4 was breakeven positive

•EPS (NTM): -$0.22, +111% YoY improvement

•ROE: -67.4%, distorted by negative equity dynamics

•Debt/Equity: 324.6%, elevated leverage

•Quarterly trajectory: $0.33b to $0.38b revenue across the last four quarters

Forward Outlook

•Revenue guidance: FY26 raised to $1.595b to $1.605b, NTM consensus $1.60b (+23.2%)

•EPS estimates: NTM -$0.22, turning positive at $0.03 by FY+2

•FY+2 revenue estimate: $1.97b, implying roughly 23% CAGR

•Margin trajectory: operating leverage building as data/AI mix grows; path to positive EBIT within 4 to 6 quarters

•Personalis integration expected to add MRD revenue and cross sell into the existing oncology channel

Valuation Analysis

•NTM P/S: 8.1x on $1.60b forward revenue

•NTM P/E: not meaningful (negative EPS)

•FY+2 P/S: ~8.0x on $1.97b at current market cap of $15.7b

•FY+2 P/E: not meaningful at $0.03 EPS

•Trailing P/S (TTM): ~11.0x

•DCF cross check: WACC 10%, terminal growth 3%, sustained 20%+ growth and mid teens long run EBIT margins supports roughly $60 to $75 fair value

•Peer comparison:

◦Guardant Health: ~7x NTM P/S, slower growth, similar losses

◦Natera: ~9x NTM P/S, profitable inflection further along

◦Exact Sciences: ~4x NTM P/S, mature diagnostics growth

◦Veeva (data/software adjacency): ~14x NTM P/S, 40%+ operating margins

•Consensus price target: $72.60 (range $50 to $92), essentially at the current price

•Fair value range: $62 to $78, with the bull case requiring successful Personalis integration and sustained 25%+ growth

Key Risks & Catalysts

Risks

•Heavy insider selling: 68 open market sells, -$59.7m net, led by CEO Lefkofsky (-$52.6m)

•Personalis acquisition integration risk and potential margin dilution

•Elevated leverage at 325% debt/equity limits financial flexibility

•Reimbursement pressure on NGS testing could compress diagnostics revenue per test

•13F data shows institutional holder count collapsing (-538 QoQ), suggesting weak sponsorship (data quality caveat applies)

•Valuation leaves little room for execution misses at 8x forward sales

Catalysts

•Q3 earnings and updated FY26 guidance

•Personalis deal close and MRD revenue ramp

•New biopharma foundation model and data licensing contracts (AstraZeneca template)

•First full quarter of positive adjusted EBIT would de-risk the profitability narrative

•Investor day disclosures on long term margin targets

Investment Thesis

Tempus is one of the few scaled, pure play AI in healthcare assets, with a genuine data moat, 23%+ growth, expanding gross margins and a credible path to profitability within two years. The Personalis deal is strategically sound, extending leadership into MRD, the fastest growing segment of oncology diagnostics.

However, at $71.98 the stock trades at 8.1x NTM sales, essentially in line with the $72.60 consensus target and our $62 to $78 fair value range. The combination of aggressive insider selling, elevated leverage and integration risk tilts the risk/reward to neutral at current levels.

Recommendation: HOLD. Accumulate on pullbacks toward $55 to $60 (roughly 6.5x NTM sales) where the growth and margin inflection story offers compelling asymmetry. A sustained move above $92 would require evidence of MRD synergies and durable positive EBIT.

Written by Buy Side Bro's AI analyst from financials, consensus, filings and recent news. General information only, not financial advice.

Tempus AI, Inc. TEM

Bro's Verdict
Deep Dive

Executive Summary

Business Model & Competitive Position

Financial Snapshot

Forward Outlook

Valuation Analysis

Key Risks & Catalysts

Investment Thesis

Run your own analysis free

Bro's VerdictDeep Dive

Executive Summary

Business Model & Competitive Position

Financial Snapshot

Forward Outlook

Valuation Analysis

Key Risks & Catalysts

Investment Thesis

Run your own analysis free

Bro's Verdict
Deep Dive